The respiratory syncytial virus (RSV) vaccine produced strong immune responses in older adults during its first two seasons of use, according to a new study. The phase 3 randomized controlled ...
Despite 50 years of research, there are currently no RSV vaccines approved or in Phase III trials for any of the target populations. High levels of neutralizing antibodies to RSV F protein have ...
PRC vaccine leader AIM Vaccine (06660.HK) announced on February 26 that its self-developed mRNA RSV (Respiratory Syncytial Virus) vaccine has recently received clinical trial approval from the U.S ...
Britain's health regulator said on Friday it has approved Moderna's vaccine for respiratory syncytial virus in adults 60 ...
Respiratory syncytial virus (RSV), or human respiratory syncytial virus (hRSV), is a common viral respiratory infection that triggers mild, cold-like symptoms. However, at-risk populations ...
Blue Lake Biotechnology to Present Safety and Immunogenicity Data for its RSV Intranasal Vaccine Candidate at the 13th International RSV Symposium Blue Lake Biotechnology, Inc., a clinical-stage ...
Local health boards invited adults aged 75–79, including those turning 75 before July 2025, to come forward for their free RSV vaccine ahead of the winter. By the end of November 2024 ...
High vaccine uptake shows promise for the prevention of respiratory syncytial virus (RSV) in infants. The rollout of 2 major interventions to prevent severe respiratory syncytial virus (RSV ...
Despite more than 50 years of research, there are no RSV vaccines approved or in Phase III clinical trials. Key challenges include peak disease in infants less than 3 months of age and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback